Andreea M Rawlings
Overview
Explore the profile of Andreea M Rawlings including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rawlings A, Chuang R, Schmahmann J, Perlman S, Rosenthal L, Safarpour D, et al.
Mov Disord Clin Pract
. 2025 Jan;
PMID: 39876568
Background: Clinical outcomes assessments (COAs) in spinocerebellar ataxia (SCA) need to be standardized, ataxia-specific, sensitive to change, clinically relevant, and meaningful to patients. Objectives: To evaluate the longitudinal 1- and...
2.
Coles A, Achiron A, Traboulsee A, Singer B, Pozzilli C, Oreja-Guevara C, et al.
Ther Adv Neurol Disord
. 2023 Sep;
16:17562864231194823.
PMID: 37745914
Background And Objectives: Alemtuzumab demonstrated superior efficacy subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple sclerosis in the 2-year CARE-MS I and II trials. Efficacy was maintained in the...
3.
Wu A, Sharrett A, Folsom A, Alonso A, Walker K, Gottesman R, et al.
Neurology
. 2023 Aug;
101(17):e1697-e1707.
PMID: 37652701
Background And Objectives: Blood concentrations of hemostatic factors affect thrombosis and bleeding diathesis and may contribute to cognitive impairment through modifiable vascular pathologies. Whether hemostasis, assessed in middle age, is...
4.
Waitzfelder B, Palaniappan L, Varga A, Frankland T, Li J, Daida Y, et al.
BMC Public Health
. 2023 May;
23(1):885.
PMID: 37189145
Background: Cardiovascular disease (CVD) remains the leading cause of death in the US. CVD incidence is influenced by many demographic, clinical, cultural, and psychosocial factors, including race and ethnicity. Despite...
5.
Wilken J, Traboulsee A, Nelson F, Ionete C, Kolind S, Fratto T, et al.
Mult Scler Relat Disord
. 2023 Apr;
73:104677.
PMID: 37028124
Background: Alemtuzumab is effective in reducing relapse rate and disability, but limited data exist on its effect on cognitive function in relapsing multiple sclerosis (RMS). The present study assessed neurocognitive...
6.
Kuhle J, Chitnis T, Banwell B, Tardieu M, Arnold D, Rawlings A, et al.
Mult Scler
. 2023 Jan;
29(3):385-394.
PMID: 36632983
Background: The phase 3 TERIKIDS study demonstrated efficacy and manageable safety for teriflunomide versus placebo in children with relapsing multiple sclerosis (RMS). Objective: Evaluate plasma neurofilament light chain (pNfL) concentrations...
7.
Berkovich R, Negroski D, Wynn D, Sellers D, Bzdek K, Lublin A, et al.
Mult Scler Relat Disord
. 2022 Dec;
70:104472.
PMID: 36566698
Background: The prevalence of multiple sclerosis (MS) in older people is increasing due to population aging and availability of effective disease-modifying therapies (DMTs). Treating older people with MS is complicated...
8.
Wray S, Jacques F, Miller T, Nicholas J, Arroyo R, Travis L, et al.
Mult Scler J Exp Transl Clin
. 2022 Nov;
8(4):20552173221135888.
PMID: 36407472
Background: Patient-reported outcomes are increasingly used in the management of patients with multiple sclerosis to understand the patient's perspective of disease and treatment. These measures provide insights into important factors...
9.
Schmidt M, Groom H, Rawlings A, Mattison C, Salas S, Burke R, et al.
Emerg Infect Dis
. 2022 Oct;
28(11):2234-2242.
PMID: 36285882
Knowledge of the epidemiology of sporadic acute gastroenteritis (AGE) in the United States is limited. During September 2016-September 2017, we surveyed Kaiser Permanente Northwest members in Oregon and Washington, USA,...
10.
Beksac M, Spicka I, Hajek R, Bringhen S, Jelinek T, Martin T, et al.
Leuk Res
. 2022 Sep;
122:106948.
PMID: 36108425
The Phase 3 ICARIA-MM (NCT02990338) and IKEMA (NCT03275285) studies demonstrated that isatuximab (Isa) plus pomalidomide (P) and dexamethasone (d; Isa-Pd) or carfilzomib (K) and d (Isa-Kd) improved progression-free survival (PFS)...